Studies have also leveraged PD-1/PD-L1 and CTLA4– targeting antibodies radiolabeled with 89Z for evaluating the tumor uptake of therapeutics using PET imaging; however, such measurements are associated with challenges (104). Here, CTLA4 is linked to neoplasm.